Septic shock: Lilly withdraws Xigris after 10 years on market
This article was originally published in Scrip
Executive Summary
Lilly has abruptly withdrawn its sepsis drug Xigris (drotrecogin alfa) from all markets after it failed to meet the primary endpoint of mortality reduction in a Phase III trial in septic shock. Lilly expressed surprise at the findings but others – including investigators at the Cochrane review – will applaud the decision to pull the plug on a drug that many already considered dangerous and of limited, if any, benefit.